AR110163A1 - Potenciadores bmp - Google Patents
Potenciadores bmpInfo
- Publication number
- AR110163A1 AR110163A1 ARP170103119A ARP170103119A AR110163A1 AR 110163 A1 AR110163 A1 AR 110163A1 AR P170103119 A ARP170103119 A AR P170103119A AR P170103119 A ARP170103119 A AR P170103119A AR 110163 A1 AR110163 A1 AR 110163A1
- Authority
- AR
- Argentina
- Prior art keywords
- potentizers
- bmp
- compound
- heteroalkyl
- haloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662420535P | 2016-11-10 | 2016-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110163A1 true AR110163A1 (es) | 2019-02-27 |
Family
ID=60569967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170103119A AR110163A1 (es) | 2016-11-10 | 2017-11-09 | Potenciadores bmp |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10259827B2 (enExample) |
| EP (1) | EP3538531A1 (enExample) |
| JP (1) | JP2019534302A (enExample) |
| KR (1) | KR20190075120A (enExample) |
| CN (1) | CN109923118A (enExample) |
| AR (1) | AR110163A1 (enExample) |
| AU (1) | AU2017357719A1 (enExample) |
| BR (1) | BR112019009404A2 (enExample) |
| CA (1) | CA3043575A1 (enExample) |
| EA (1) | EA201991141A1 (enExample) |
| MX (1) | MX2019005504A (enExample) |
| RU (1) | RU2019117548A (enExample) |
| TW (1) | TW201821076A (enExample) |
| UY (1) | UY37477A (enExample) |
| WO (1) | WO2018087677A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119751235A (zh) * | 2019-01-23 | 2025-04-04 | 约翰霍普金斯大学 | 非免疫抑制性fk506类似物及其用途 |
| WO2026059989A1 (en) * | 2024-09-10 | 2026-03-19 | Montara Therapeutics, Inc. | Peripheral blockers for central nervous system-selective drug activity |
| WO2026060005A1 (en) * | 2024-09-10 | 2026-03-19 | Montara Therapeutics, Inc. | Macrocyclic blockers for use in the reduction of peripheral side effects due to everolimus therapy |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0346427B1 (en) | 1987-12-09 | 1995-03-29 | FISONS plc | Macrocyclic compounds |
| EP0378318A1 (en) | 1989-01-11 | 1990-07-18 | Merck & Co. Inc. | Process for synthesis of FK-506 and tricarbonyl intermediates |
| GR1001225B (el) | 1989-09-14 | 1993-06-30 | Fisons Plc | Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους. |
| GB9014136D0 (en) * | 1990-06-25 | 1990-08-15 | Fujisawa Pharmaceutical Co | Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same |
| DE4028664A1 (de) * | 1990-09-10 | 1992-03-12 | Sandoz Ag | Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung |
| DE4028676A1 (de) * | 1990-09-10 | 1992-03-12 | Sandoz Ag | Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung |
| DE4028677A1 (de) * | 1990-09-10 | 1992-03-12 | Sandoz Ag | Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung |
| DE4028675A1 (de) * | 1990-09-10 | 1992-03-12 | Sandoz Ag | Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung |
| DE4028666A1 (de) * | 1990-09-10 | 1992-03-12 | Sandoz Ag | Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung |
| CA2071332A1 (en) * | 1991-06-25 | 1992-12-26 | Laszlo R. Treiber | C-21 hydroxylated fk-506 antagonist |
| GB9202196D0 (en) | 1992-02-01 | 1992-03-18 | Fisons Plc | Method of treatment |
| US5284877A (en) * | 1992-06-12 | 1994-02-08 | Merck & Co., Inc. | Alkyl and alkenyl macrolides having immunosuppressive activity |
| GB9218027D0 (en) | 1992-08-25 | 1992-10-14 | Fisons Plc | Novel method of treatment |
| GB9218597D0 (en) | 1992-08-25 | 1992-10-14 | Fisons Plc | Novel method of treatment |
| US7109317B1 (en) * | 1998-11-06 | 2006-09-19 | President And Fellows Of Harvard College | FK506-based regulation of biological events |
| WO2000058318A1 (en) | 1999-03-31 | 2000-10-05 | Abbott Laboratories | Phosphate containing macrocyclic immunomodulators |
| US6569867B2 (en) | 1999-10-01 | 2003-05-27 | Kosan Biosciences, Inc. | Polyketide derivatives |
| EP1282626A2 (en) | 2000-05-17 | 2003-02-12 | Kosan Biosciences, Inc. | Polyketide derivatives |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| AU2006206525A1 (en) * | 2005-01-20 | 2006-07-27 | Array Biopharma Nc. | Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases |
| WO2012047762A2 (en) | 2010-10-08 | 2012-04-12 | Amplyx Pharmaceuticals, Inc. | Antifungal agents |
| WO2015106283A1 (en) | 2014-01-13 | 2015-07-16 | Amplyx Pharmaceuticals, Inc. | Antifungal compounds |
-
2017
- 2017-11-08 CA CA3043575A patent/CA3043575A1/en not_active Abandoned
- 2017-11-08 MX MX2019005504A patent/MX2019005504A/es unknown
- 2017-11-08 BR BR112019009404A patent/BR112019009404A2/pt not_active Application Discontinuation
- 2017-11-08 EP EP17808588.2A patent/EP3538531A1/en not_active Withdrawn
- 2017-11-08 JP JP2019524240A patent/JP2019534302A/ja not_active Ceased
- 2017-11-08 RU RU2019117548A patent/RU2019117548A/ru not_active Application Discontinuation
- 2017-11-08 CN CN201780069068.7A patent/CN109923118A/zh active Pending
- 2017-11-08 AU AU2017357719A patent/AU2017357719A1/en not_active Abandoned
- 2017-11-08 EA EA201991141A patent/EA201991141A1/ru unknown
- 2017-11-08 US US15/807,462 patent/US10259827B2/en active Active
- 2017-11-08 KR KR1020197016038A patent/KR20190075120A/ko not_active Withdrawn
- 2017-11-08 TW TW106138532A patent/TW201821076A/zh unknown
- 2017-11-08 WO PCT/IB2017/056991 patent/WO2018087677A1/en not_active Ceased
- 2017-11-09 UY UY0001037477A patent/UY37477A/es not_active Application Discontinuation
- 2017-11-09 AR ARP170103119A patent/AR110163A1/es unknown
-
2019
- 2019-02-26 US US16/286,002 patent/US20190194227A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA3043575A1 (en) | 2018-05-17 |
| BR112019009404A2 (pt) | 2019-07-30 |
| US20180127436A1 (en) | 2018-05-10 |
| AU2017357719A1 (en) | 2019-05-16 |
| MX2019005504A (es) | 2019-08-12 |
| TW201821076A (zh) | 2018-06-16 |
| RU2019117548A (ru) | 2020-12-10 |
| JP2019534302A (ja) | 2019-11-28 |
| CN109923118A (zh) | 2019-06-21 |
| WO2018087677A1 (en) | 2018-05-17 |
| UY37477A (es) | 2018-06-29 |
| US10259827B2 (en) | 2019-04-16 |
| US20190194227A1 (en) | 2019-06-27 |
| EA201991141A1 (ru) | 2019-10-31 |
| KR20190075120A (ko) | 2019-06-28 |
| EP3538531A1 (en) | 2019-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110381A2 (es) | Inhibidores biarilo de tirosina cinasa de bruton | |
| EA201792536A1 (ru) | Триазоловые агонисты рецептора apj | |
| MX2018008815A (es) | Inhibidores de tirosina quinasa de bruton. | |
| GEAP202015005A (en) | Diacylglycerol acyltransferase 2 inhibitors | |
| EA201791305A1 (ru) | Конденсированные пиримидины для лечения вич | |
| MA47460A (fr) | Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase | |
| EA201891024A1 (ru) | Соединения-ингибиторы tank-связывающей киназы | |
| EA201991697A1 (ru) | Сульфоксиминовые ингибиторы гликозидазы | |
| CR20170099A (es) | Pirrolobenzodiazepinas y conjugados de anticuerpos-disulfuro de las mismas | |
| AR110125A1 (es) | Compuestos poliméricos que liberan sulfuro de hidrógeno | |
| AR104342A1 (es) | Compuesto heterocíclico | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| EA201992147A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| EP3415146A4 (en) | INHIBITOR OF INFLAMMASOMAL ACTIVATION | |
| MX2016017405A (es) | Compuestos derivados de 2-(3-piridinil)-1h-benzimidazol y medicamentos que los contienen. | |
| EA201690523A1 (ru) | Триазолопиридины, композиции и способы их применения | |
| MX394157B (es) | Derivado de dihidropirrolopirazol sustituido. | |
| MA45552A (fr) | Compositions destinées au traitement de l'amylose | |
| NI201800065A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento de cáncer | |
| MA43764A (fr) | Inhibiteur monovalent de l'interaction hutnfr1 | |
| EA201991141A1 (ru) | Усилители bmp | |
| MA53009A (fr) | Agents inhibiteurs d'ask1 | |
| PH12017500492A1 (en) | Crystalline bace inhibitors | |
| UY37339A (es) | Formas de sal de 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il)-6-(2,2,6,6-tetrametiltetrahidro-2h-piran-4-il)piridin-3-il)-1himidazol-2-carboxamida y composiciones que las contienen | |
| AR107163A1 (es) | Inhibidores de quinasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |